JNJ·NYSE·US
Johnson & Johnson
Johnson & Johnson is a diversified healthcare company with two major operating areas: Innovative Medicine and MedTech. It develops and sells pharmaceuticals, biologics, and medical devices including surgical systems and diagnostics-related products.
Recent Activity
Updated Oct 31, 2026
–The European Commission approved Johnson & Johnson's TECVAYLI (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse.
–The approval is based on Phase 3 results showing significant progression-free and overall survival benefits for teclistamab.
–Subcutaneous RYBREVANT (amivantamab) showed a 77% overall response rate in first-line treatment of certain types of advanced head and neck squamous cell carcinoma.
–Complete responses were seen in 14% of patients with head and neck squamous cell carcinoma other than HPV-associated oropharyngeal cancer.
–Johnson & Johnson reported early-stage trial results for its prostate cancer drug JNJ-6143 in patients with advanced prostate cancer, with the drug shrinking tumors.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.
Recent Discoveries
Recent discoveries are part of the Pro plan.
Ended Relationships
Management Perspective on Regulatory & Geopolitical Developments
Related Events
1 event · Related events are part of the Pro plan.